XML 48 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information and Concentration of Business Risk, Segment Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2017
USD ($)
Segment
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Segment Information and Concentration of Business Risk [Abstract]      
Number of reportable segments | Segment 2    
Commercial Revenue [Abstract]      
SPINRAZA royalties $ 5,211 $ 0  
Licensing and other royalty revenue 3,547 1,660  
Total commercial revenue 8,758 1,660  
R&D revenue under collaborative agreements 101,546 35,214  
Total segment revenue 110,304 36,874  
Income (loss) from operations 13,989 (54,652)  
Total assets 1,083,996   $ 912,467
Operating Segments [Member] | Ionis Core [Member]      
Commercial Revenue [Abstract]      
SPINRAZA royalties 5,211    
Licensing and other royalty revenue 3,547 1,660  
Total commercial revenue 8,758    
R&D revenue under collaborative agreements 143,425 35,214  
Total segment revenue 152,183 36,874  
Income (loss) from operations 73,832 (38,567)  
Total assets 1,202,164   1,067,770
Operating Segments [Member] | Akcea Therapeutics [Member]      
Commercial Revenue [Abstract]      
SPINRAZA royalties 0    
Licensing and other royalty revenue 0 0  
Total commercial revenue 0    
R&D revenue under collaborative agreements 9,597 0  
Total segment revenue 9,597 0  
Income (loss) from operations (59,873) (16,049)  
Total assets 132,982   10,684
Elimination of Intercompany Activity [Member]      
Commercial Revenue [Abstract]      
SPINRAZA royalties 0    
Licensing and other royalty revenue 0 0  
Total commercial revenue 0    
R&D revenue under collaborative agreements (51,476) 0  
Total segment revenue (51,476) 0  
Income (loss) from operations 30 $ (36)  
Total assets $ (251,150)   $ (165,987)